First-in-human trial primes immune system to accept donor livers
medicalxpress - UPMC and University of Pittsburgh clinician-scientists have weaned and kept multiple liver transplantation patients off of all immunosuppressant drugs for more than three years through a first-in-human clinical trial of a unique "immune priming" therapy.
AI Summary: A first‑in‑human study reports a novel immune‑priming approach that enabled three liver transplant recipients to stop standard lifelong immunosuppression. The intervention appears to induce tolerance to donor tissue, reducing dependence on anti‑rejection drugs and their toxic side effects, offering a potential shift in transplant management if larger trials confirm these early results.
Related Stories
Experimental therapy significantly reduces Parkinson’s toxic protein in early trial / 2 months
Drug-induced hibernation shows promise to limit stroke brain injury / 21 days
BioMarin Phase 3 failure dims hopes for rare‑disease therapy / 7 wks
Insmed shelves Brinsupri in skin indication after mid‑stage flop / 3 months
Sanofi ousts Paul Hudson as Belén Garijo named incoming CEO / 4 months
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 7 days
Teclistamab shows survival benefit prompting earlier use discussions / 21 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Olfaction, Clinical Trials, Digital Health, Product Recall and look for the RSS link.
StackHealth Time Machine